Full text is available at the source.
Abstract
Ibogaine may affect multiple brain neurotransmitters.
- It interacts with μ and κ opioid receptors, dopamine, serotonin, N-methyl-D-aspartate, and nicotinic acetylcholine receptors.
- Its anti-addiction effects may be linked to activity on nicotinic acetylcholine receptors in a specific brain area.
- Ibogaine could potentially cause serious heart issues, such as QTc prolongation and polymorphic ventricular tachycardia in some cases.
- In a study with 30 participants, no serious adverse events were reported while using ibogaine.
- A phase 1/2a study on ibogaine has been completed, but no adverse event results are available yet.
- Further research is needed to fully understand ibogaine's safety and its potential for treating opioid dependence.
Simplified